Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eloxx Pharmaceuticals Inc (NQ: ELOX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
From Eloxx Pharmaceuticals
Via GlobeNewswire
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 8/30
Via Investor Brand Network
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 4/10
Via Investor Brand Network
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
From Eloxx Pharmaceuticals
Via GlobeNewswire
This Small Cap Stock Surged Over 100%
Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer. 
Via MarketBeat
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study 
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
Topline results expected in first half of 2023 
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022 
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
Trial sites now open in Australia and the United Kingdom 
From Eloxx Pharmaceuticals
Via GlobeNewswire
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
Via FinancialNewsMedia
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.